Nature Reviews Clinical Oncology - Table of Contents alert Volume 12 Issue 12

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
December 2015 Volume 12 Number 12
Impact Factor 14.180 *	In this issue Research Highlights News and Views Reviews Perspectives Correction Also this month  Featured article: Precision medicine for metastatic breast cancer—limitations and solutions Monica Arnedos, Cecile Vicier, Sherene Loi, Celine Lefebvre, Stefan Michiels, Herve Bonnefoi & Fabrice Andre
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Guides for Patients: Reliable medical information for cancer patients. The ESMO - Anticancer Fund Patient Guides series, based on the ESMO Clinical Practice Guidelines are available in 17 different tumour types, 10 different languages and more coming soon. All downloadable from esmo.org and anticancerfund.org or from the ESMO Cancer Guides Mobile App.
Advertisement
An online-only, open access, multidisciplinary journal dedicated to publishing high-quality original research articles, reviews, editorials, commentaries, and hypothesis generating observations on all areas of breast cancer research. Part of the Nature Partner Journals series, published in partnership with the Breast Cancer Research Foundation. Now open for submissions
RESEARCH HIGHLIGHTS Top Prostate cancer: Molecular stratification and repair defects: revealing hidden treasures Published online: 17 November 2015 p683 | doi:10.1038/nrclinonc.2015.205 PDF Haematological cancer: Can FCR be curative in CLL? Published online: 17 November 2015 p684 | doi:10.1038/nrclinonc.2015.206 PDF Melanoma: Therapy combinations: celebrating more milestones Published online: 27 October 2015 p685 | doi:10.1038/nrclinonc.2015.179 PDF Lung cancer: Nivolumab—an effective second-line treatment for NSCLC Published online: 20 October 2015 p685 | doi:10.1038/nrclinonc.2015.184 PDF Gynaecological cancer: Therapeutic HPV vaccine holds promise Published online: 13 October 2015 p686 | doi:10.1038/nrclinonc.2015.180 PDF In the news: From ECC 2015 Published online: 13 October 2015 p686 | doi:10.1038/nrclinonc.2015.185 PDF Gastrointestinal cancer: mDCF—new standard-of-care? Published online: 20 October 2015 p686 | doi:10.1038/nrclinonc.2015.188 PDF IN BRIEF FROM ECC 2015—neuroendocrine cancer: RADIANT-4 trial—NET improvement with everolimus? | FROM ECC 2015—neuroendocrine cancer: SSA therapies—177Lu-DOTATATE is a better one in NETTER-1 | FROM ECC 2015—lung cancer: Novelty of Rova-T—first targeted agent for SCLC PDF Clinical Oncology JOBS of the week Research Fellow Molecular Medicine / Oncology Mayo Clinic W2 Professor for Translational Oncology (life-time position) Rheinische Friedrich-Wilhelms-Universitat Assistant / Associate Professor - Radiation Oncology Dana-Farber Cancer Institute (DFCI) Tenure-track Faculty Position in Cancer / Radiation Oncology / Medical Imaging Université de Sherbrooke More Science jobs from Clinical Oncology EVENT World Congress and Expo on Oncology & Radiology (Oncology-2016) 18.04.16 Dubai More science events from
NEWS AND VIEWS		Top
Urological cancer: CHAARTED/GETUG 12—docetaxel in non-castrate prostate cancers Min Yuen Teo & Howard I. Scher Published online: 10 November 2015 p687 | doi:10.1038/nrclinonc.2015.192 In two recent phase III trials, investigators evaluated the addition of docetaxel to androgen-deprivation therapy for non-castrate prostate cancer. On the basis of the CHAARTED-trial findings, we can firmly conclude that this combination can be used in the metastatic setting. The results of the GETUG 12 trial are less informative, although some benefit for patients with high-risk localized prostate cancer was demonstrated. Full Text | PDF
Chemotherapy: Adjuvant TKIs in NSCLC: what can we learn from RADIANT? Fred R. Hirsch & Paul A. Bunn Jr Published online: 10 November 2015 p689 | doi:10.1038/nrclinonc.2015.202 In the RADIANT study, no difference in disease-free survival was observed for patients with non-small-cell lung cancer (NSCLC) treated with erlotinib versus placebo in the adjuvant setting. Further biomarker studies are awaited to determine whether patients with NSCLC can benefit from adjuvant therapy with tyrosine kinase inhibitors. Full Text | PDF
Breast cancer: Chemotherapy and the recurrence score—results as expected? Lajos Pusztai Published online: 10 November 2015 p690 | doi:10.1038/nrclinonc.2015.191 A study assessing the impact of the 21-gene recurrence score assay in routine clinical practice on the use of adjuvant chemotherapy in women with early stage ER-positive breast cancers showed that adjuvant chemotherapy use decreased in high-risk patients, but increased in low-risk patients. I discuss these results and highlight how this reflects more-selective administration of chemotherapy. Full Text | PDF
REVIEWS		Top
Precision medicine for metastatic breast cancer—limitations and solutions Monica Arnedos, Cecile Vicier, Sherene Loi, Celine Lefebvre, Stefan Michiels, Herve Bonnefoi & Fabrice Andre Published online: 21 July 2015 p693 | doi:10.1038/nrclinonc.2015.123 The development of precision medicine for the management of metastatic breast cancer is an appealing concept; however, major scientific and logistical challenges hinder its implementation in the clinic. The authors discuss the limitations, including the identification of driver events, and the possible solutions to the application of precision medicine in the management of patients with metastatic disease, which include scaling-up the number of patients screened for identifying a genomic alteration, the clustering of genomic alterations into pathways, and the development of personalized medicine trials. Abstract | Full Text | PDF
Post-transplantation malignancies: here today, gone tomorrow? Edward K. Geissler Published online: 20 October 2015 p705 | doi:10.1038/nrclinonc.2015.186 The incidence of cancer in transplant recipients is indisputably higher than that of the age-matched general population, and the increased cancer development in transplant recipients who require immunosuppression to avoid graft rejection is well recognized. This Review discusses the advances with mTOR inhibitors that interfere with tumour development via immune and non-immune mechanisms, and the current and future perspectives on how best to normalize the unacceptably high rates of post-transplantation malignancies are highlighted. Abstract | Full Text | PDF
Systems biology approaches to adverse drug effects: the example of cardio-oncology Sherry-Ann Brown, Nicole Sandhu & Joerg Herrmann Published online: 13 October 2015 p718 | doi:10.1038/nrclinonc.2015.168 Cardiotoxic effects of chemotherapy can occur in various different ways depending upon the type of chemotherapy used and various patient characteristics. In this Review, the authors describe the established cardiotoxic effects of anthracyclines and HER2 inhibitors, and describe a systems medicine approach that might enable the optimal management of acute and chronic cardiotoxcities in patients who are receiving, or have received, these therapies. Abstract | Full Text | PDF | Supplementary information
PERSPECTIVES		Top
OPINION Drug repurposing in oncology—patient and health systems opportunities Francesco Bertolini, Vikas P. Sukhatme & Gauthier Bouche Published online: 20 October 2015 p732 | doi:10.1038/nrclinonc.2015.169 Repurposing approved, non-anticancer drugs is an attractive strategy for patients with cancer. To date, successes in oncology drug repurposing have been limited, despite strong evidence supporting the use of many different drugs. A lack of financial incentives for drug developers and limited drug development experience within the non-profit sector are key reasons for this lack of success. The authors discuss these issues and offer solutions to seize this opportunity in the interest of patients and societies, globally. Abstract | Full Text | PDF
CORRECTION		Top
CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival Clemens Thoma Published online: 10 November 2015 p742 | doi:10.1038/nrclinonc.2015.207 Full Text | PDF
Advertisement
Nature Index 2015 Collaborations The Nature Index database - with its focus on high-quality science articles - lends itself well to the analysis of collaboration patterns both between institutions and countries. Nature Index 2015 Collaborations paints a rich picture of the global research ecosystem and yields insights into the power a nd impact of joint research.  Access now for free. htt
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2015. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.